Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

11.06
+0.20001.84%
Post-market: 11.05-0.0100-0.09%18:45 EDT
Volume:937.70K
Turnover:10.47M
Market Cap:687.47M
PE:-8.86
High:11.45
Open:10.75
Low:10.67
Close:10.86
52wk High:11.45
52wk Low:4.50
Shares:62.16M
Float Shares:55.78M
Volume Ratio:0.75
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.68
PE(LYR):-7.00

Loading ...

Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8

MT Newswires Live
·
Sep 09

Sagimet Biosciences Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 09

Sagimet Biosciences initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
Sep 09

Sagimet Biosciences Inc. : Barclays Raises to Overweight from Equal-Weight; Raises Target Price to $18 from $8

THOMSON REUTERS
·
Sep 09

U.S. Research Roundup-Argan, Mastec, Oracle

Reuters
·
Sep 09

Sagimet Biosciences to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 02

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Sagimet Biosciences Price Target Maintained with a $29.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 25

Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained

TIPRANKS
·
Aug 25

Sagimet Biosciences advances AURORA clinical trial

TIPRANKS
·
Aug 25

Sagimet Advances Aurora Phase 3 Acne Trial of Denifanstat, Targets Q4 2026 Enrollment

Reuters
·
Aug 25

Sagimet Biosciences Advances Aurora U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences - Patient Screening for Aurora Phase 3 Trial to Begin in October 2026

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences Inc.: Anticipate Submitting an Nda upon Completion of 12-Week Phase of Study

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences - All Clinical Trial Sites Identified and Cro Retained for Aurora Phase 3 Trial

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences Grants 260,700 Inducement Stock Options to New Hires

Reuters
·
Aug 18

Sagimet Biosciences Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 18

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 18

Sagimet Biosciences price target raised to $56 from $49 at Canaccord

TIPRANKS
·
Aug 17

Sagimet Wins FDA IND Clearance for Phase 3 Denifanstat Acne Trial

Reuters
·
Aug 13